as a result of the uncertainties discussed above , the uncertainty associated with clinical trial enrollments and the risks inherent in the development process , we are unable to determine the duration and completion costs of current or future clinical stages of our product candidates or when , or to what extent , we will generate revenues from the commercialization and sale of any of our product candidates . development timelines , probability of success and development costs vary widely . r & d expense for the year ended december 31 , 2013 increased significantly compared to the year ended december 31 , 2012 , due to fully enrolling our pivotal phase iii clinical study by the end of 2013 and manufacturing services as provided by biotest under our license agreement with them . we expect that our r & d expense will increase throughout 2014 , primarily attributable to the further development of ri-002 and our related clinical phase iii program . general and administrative expense general and administrative , or g & a expense , consists of rent , maintenance and utilities , insurance , wages , stock-based compensation and benefits for senior management and staff unrelated to r & d , legal fees , accounting and auditing fees , information technology , travel and other expenses related to the general operations of the business . g & a expense for the current year also includes a write-off of deferred financing fees related to our financing . we expect that our g & a expense will continue to increase in 2014 as a result of operating as a publicly traded company as a result of increased listing fees of our common stock and the hiring of additional staff . interest income and interest expense interest income consists of interest earned on our cash and cash equivalents . interest expense consists of interest incurred on our notes payable and previous convertible notes up to their automatic conversion into our common stock upon the completion of our private placement in february 2012 , as well as the amortization and write-off of deferred financing costs and debt discounts and a charge for the beneficial conversion feature relating to our notes payable and previous convertible notes . results of operations year ended december 31 , 2013 compared to year ended december 31 , 2012 summary table the following table presents a summary of our results of operations for the year ended december 31 , 2013 compared to the year ended december 31 , 2012 . 38 index replace_table_token_1_th revenue we recorded revenue of $ 3,067,577 during the year ended december 31 , 2013 compared to $ 1,118,118 during the year ended december 31 , 2012. product revenue was $ 3,023,503 for the year ended december 31 , 2013 , from the sale of blood plasma collected in our fda-licensed , gha-certified georgia based blood plasma collection center compared to product revenue of $ 1,118,118 for the year ended december 31 , 2012. product revenue for the year ended december 31 , 2013 was primarily attributed to sales made pursuant to our plasma supply agreement with biotest during june 2012 , under which biotest purchases normal source plasma from our georgia facility to be used in their manufacturing . the increase in product revenue of $ 1,905,385 was attributed to increased advertising and promotions to attract more plasma donors as well as the expansion of additional plasma donor equipment . for the year ended december 31 , 2013 , license revenue was $ 44,074 , which relates to services provided by biotest in accordance with our license agreement with them . there was no license revenue for the same period in 2012. we have not generated any revenue from our therapeutics , research and development business . cost of product revenue cost of product revenue was $ 2,023,441 for the year ended december 31 , 2013 , an increase of $ 1,354,385 from $ 669,056 for the year ended december 31 , 2012. the increased cost of product revenues for the year ended december 31 , 2013 was related to the costs associated with the increased production and sale of normal source plasma . research and development expenses research and development expenses were $ 9,303,077 for the year ended december 31 , 2013 , an increase of $ 5,833,999 from $ 3,469,078 for the year ended december 31 , 2012. research and development expenses consist of consulting expenses relating to regulatory affairs , quality control and manufacturing , assay development and ongoing testing costs , clinical trial costs and fees , drug product manufacturing including the cost of plasma , plasma storage and transportation costs , as well as wages and benefits for staff directly related to the research and development of ri-002 . research and development expenses increased primarily as a result of higher manufacturing , testing , and regulatory costs for our phase iii clinical study , which has completed enrollment and related wages and stock-based compensation expense during the year ended december 31 , 2013 . 39 index plasma center operating expenses plasma center operating expenses were $ 2,418,156 for the year ended december 31 , 2013 , an increase of $ 671,292 from $ 1,746,864 for the year ended december 31 , 2012. plasma center operating expenses consist of general and administrative overhead , including rent , maintenance and utilities , wages and benefits for center staff , plasma collection supplies , plasma transportation and storage ( off-site ) , advertising and promotion expenses , and computer software fees related to donor collections . the increase in plasma center expenses was primarily a result of increased donor collections during the year ended december 31 , 2013. we expect that as plasma collection increases , our plasma center operating expenses will also increase accordingly . story_separator_special_tag the financial accounting standards board has issued certain accounting pronouncements as of december 31 , 2013 that will become effective in subsequent periods ; however , we do not believe that any of those pronouncements would have significantly affected our financial accounting measurements or disclosures had they been in effect during the year ended december 31 , 2013 or that they will have a significant impact at the time they become effective . critical accounting policies and estimates on april 5 , 2012 , the jobs act was signed into law . the jobs act contains provisions that , among other things , reduce certain reporting requirements for qualifying public companies . as an “ emerging growth company , ” we may , under section 7 ( a ) ( 2 ) ( b ) of the securities act , delay adoption of new or revised accounting standards applicable to public companies until such standards would otherwise apply to private companies . we may take advantage of this extended transition period until the first to occur of the date that we ( i ) are no longer an “ emerging growth company ” or ( ii ) affirmatively and irrevocably opt out of this extended transition period . we have elected to take advantage of the benefits of this extended transition period . our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards . until the date that we are no longer an “ emerging growth company ” or affirmatively and irrevocably opt out of the exemption provided by securities act section 7 ( a ) ( 2 ) ( b ) , upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies , we will disclose the date on which adoption is required for non-emerging growth companies and the date on which we will adopt the recently issued accounting standard . 44 index this management 's discussion and analysis of financial condition and results of operations is based on our financial statements , which have been prepared in accordance with accounting principles generally accepted in the united states of america , or gaap . the preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets , liabilities , revenues and expenses . on an ongoing basis , we evaluate these estimates and assumptions , including those described below . we base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances . these estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources . actual results and experiences may differ materially from these estimates . some of the estimates and assumptions we have to make under gaap require difficult , subjective and or complex judgments about matters that are inherently uncertain and , as a result , actual results could differ from those estimates . due to the estimation processes involved , the following summarized accounting policies and their application are considered to be critical to understanding our business operations , financial condition and results of operations . stock-based compensation stock-based compensation cost is measured at grant date , based on the estimated fair value of the award , and is recognized as expense over the employee 's requisite service period on a straight-line basis . we account for stock options granted to non-employees on a fair value basis using the black-scholes option pricing model . the non-cash charge to operations for non-employee options with vesting are revalued at the end of each reporting period based upon the change in the fair value of the options and amortized to consulting expense over the related contract service period . for the purpose of valuing options and warrants granted to our employees , non-employees and directors and officers during the year ended december 31 , 2013 , we used the black-scholes option pricing model . we granted options to purchase an aggregate of 84,134 shares of common stock during the year ended december 31 , 2013. the options were granted to non-executive employees . to determine the risk-free interest rate , we utilized the u.s. treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards . the expected term of the options granted is in accordance with staff accounting bulletin 107 which is based the average between vesting term and contractual term . the expected dividend yield reflects our current and expected future policy for dividends on our common stock . the expected stock price volatility for our stock options was calculated by examining historical volatilities for similar publicly traded industry peers , since we do not have any trading history for our common stock . we will continue to analyze the expected stock price volatility and expected term assumptions as historical data for our common stock becomes available . we have not experienced any material forfeitures of stock options and as such , have not established a forfeiture rate . since the stock options currently outstanding are primarily held by our senior management and directors , we will continue to evaluate the effects of such future potential forfeitures , as they may arise , to evaluate our estimated forfeiture rate . due to our limited history , we use the simplified method to determine the expected life of the option grants . research and development costs our expenses include all research and development costs as incurred including the disposition of plasma and equipment for which there is no alternative future use . such expenses include costs associated with planning and conducting clinical trials . 45 index our agreement with biotest includes the in-license of certain rights to

net cash used in operating activities net cash used in operating activities was $ 10,887,154 for the year ended december 31 , 2013. the net loss for this period was higher than net cash used in operating activities by $ 4,640,092 , which was primarily attributable to increases in inventory of $ 403,465 , prepaid expenses of $ 190,969 mostly related to our phase iii vendor payments for clinical sites , manufacturing and clinical research organization services , deferred revenue of $ 1,700,000 related to license revenue , accounts payable of $ 1,608,980 related to increased clinical and manufacturing expense and timing of payments incurred with our vendors and service providers and a decrease in other assets of $ 593,051 comprised of the elimination of our restricted cash balance requirement by our landlord of $ 452,000 through meeting our rental obligations , offset by stock-based compensation of $ 888,295 and depreciation and amortization of $ 210,633. net cash used in operating activities was $ 6,903,795 for the year ended december 31 , 2012. the net loss for the year ended december 31 , 2012 is higher than cash used in operating activities by $ 397,518 , as a result of increases in restricted cash related to our letter of credit for our georgia facility , inventories of finished goods normal source plasma available for sale and accrued expenses primarily relating to accrued compensation , offset by a decrease in accounts payable and non-cash expenses of stock-based compensation of $ 626,787 and depreciation and amortization of $ 182,089. net cash used in investing activities net cash used in investing activities was $ 3,131,819 for the


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash used in operating activities net cash used in operating activities was $ 10,887,154 for the year ended december 31 , 2013. the net loss for this period was higher than net cash used in operating activities by $ 4,640,092 , which was primarily attributable to increases in inventory of $ 403,465 , prepaid expenses of $ 190,969 mostly related to our phase iii vendor payments for clinical sites , manufacturing and clinical research organization services , deferred revenue of $ 1,700,000 related to license revenue , accounts payable of $ 1,608,980 related to increased clinical and manufacturing expense and timing of payments incurred with our vendors and service providers and a decrease in other assets of $ 593,051 comprised of the elimination of our restricted cash balance requirement by our landlord of $ 452,000 through meeting our rental obligations , offset by stock-based compensation of $ 888,295 and depreciation and amortization of $ 210,633. net cash used in operating activities was $ 6,903,795 for the year ended december 31 , 2012. the net loss for the year ended december 31 , 2012 is higher than cash used in operating activities by $ 397,518 , as a result of increases in restricted cash related to our letter of credit for our georgia facility , inventories of finished goods normal source plasma available for sale and accrued expenses primarily relating to accrued compensation , offset by a decrease in accounts payable and non-cash expenses of stock-based compensation of $ 626,787 and depreciation and amortization of $ 182,089. net cash used in investing activities net cash used in investing activities was $ 3,131,819 for the
```    
 Suspicious Activity Report : as a result of the uncertainties discussed above , the uncertainty associated with clinical trial enrollments and the risks inherent in the development process , we are unable to determine the duration and completion costs of current or future clinical stages of our product candidates or when , or to what extent , we will generate revenues from the commercialization and sale of any of our product candidates . development timelines , probability of success and development costs vary widely . r & d expense for the year ended december 31 , 2013 increased significantly compared to the year ended december 31 , 2012 , due to fully enrolling our pivotal phase iii clinical study by the end of 2013 and manufacturing services as provided by biotest under our license agreement with them . we expect that our r & d expense will increase throughout 2014 , primarily attributable to the further development of ri-002 and our related clinical phase iii program . general and administrative expense general and administrative , or g & a expense , consists of rent , maintenance and utilities , insurance , wages , stock-based compensation and benefits for senior management and staff unrelated to r & d , legal fees , accounting and auditing fees , information technology , travel and other expenses related to the general operations of the business . g & a expense for the current year also includes a write-off of deferred financing fees related to our financing . we expect that our g & a expense will continue to increase in 2014 as a result of operating as a publicly traded company as a result of increased listing fees of our common stock and the hiring of additional staff . interest income and interest expense interest income consists of interest earned on our cash and cash equivalents . interest expense consists of interest incurred on our notes payable and previous convertible notes up to their automatic conversion into our common stock upon the completion of our private placement in february 2012 , as well as the amortization and write-off of deferred financing costs and debt discounts and a charge for the beneficial conversion feature relating to our notes payable and previous convertible notes . results of operations year ended december 31 , 2013 compared to year ended december 31 , 2012 summary table the following table presents a summary of our results of operations for the year ended december 31 , 2013 compared to the year ended december 31 , 2012 . 38 index replace_table_token_1_th revenue we recorded revenue of $ 3,067,577 during the year ended december 31 , 2013 compared to $ 1,118,118 during the year ended december 31 , 2012. product revenue was $ 3,023,503 for the year ended december 31 , 2013 , from the sale of blood plasma collected in our fda-licensed , gha-certified georgia based blood plasma collection center compared to product revenue of $ 1,118,118 for the year ended december 31 , 2012. product revenue for the year ended december 31 , 2013 was primarily attributed to sales made pursuant to our plasma supply agreement with biotest during june 2012 , under which biotest purchases normal source plasma from our georgia facility to be used in their manufacturing . the increase in product revenue of $ 1,905,385 was attributed to increased advertising and promotions to attract more plasma donors as well as the expansion of additional plasma donor equipment . for the year ended december 31 , 2013 , license revenue was $ 44,074 , which relates to services provided by biotest in accordance with our license agreement with them . there was no license revenue for the same period in 2012. we have not generated any revenue from our therapeutics , research and development business . cost of product revenue cost of product revenue was $ 2,023,441 for the year ended december 31 , 2013 , an increase of $ 1,354,385 from $ 669,056 for the year ended december 31 , 2012. the increased cost of product revenues for the year ended december 31 , 2013 was related to the costs associated with the increased production and sale of normal source plasma . research and development expenses research and development expenses were $ 9,303,077 for the year ended december 31 , 2013 , an increase of $ 5,833,999 from $ 3,469,078 for the year ended december 31 , 2012. research and development expenses consist of consulting expenses relating to regulatory affairs , quality control and manufacturing , assay development and ongoing testing costs , clinical trial costs and fees , drug product manufacturing including the cost of plasma , plasma storage and transportation costs , as well as wages and benefits for staff directly related to the research and development of ri-002 . research and development expenses increased primarily as a result of higher manufacturing , testing , and regulatory costs for our phase iii clinical study , which has completed enrollment and related wages and stock-based compensation expense during the year ended december 31 , 2013 . 39 index plasma center operating expenses plasma center operating expenses were $ 2,418,156 for the year ended december 31 , 2013 , an increase of $ 671,292 from $ 1,746,864 for the year ended december 31 , 2012. plasma center operating expenses consist of general and administrative overhead , including rent , maintenance and utilities , wages and benefits for center staff , plasma collection supplies , plasma transportation and storage ( off-site ) , advertising and promotion expenses , and computer software fees related to donor collections . the increase in plasma center expenses was primarily a result of increased donor collections during the year ended december 31 , 2013. we expect that as plasma collection increases , our plasma center operating expenses will also increase accordingly . story_separator_special_tag the financial accounting standards board has issued certain accounting pronouncements as of december 31 , 2013 that will become effective in subsequent periods ; however , we do not believe that any of those pronouncements would have significantly affected our financial accounting measurements or disclosures had they been in effect during the year ended december 31 , 2013 or that they will have a significant impact at the time they become effective . critical accounting policies and estimates on april 5 , 2012 , the jobs act was signed into law . the jobs act contains provisions that , among other things , reduce certain reporting requirements for qualifying public companies . as an “ emerging growth company , ” we may , under section 7 ( a ) ( 2 ) ( b ) of the securities act , delay adoption of new or revised accounting standards applicable to public companies until such standards would otherwise apply to private companies . we may take advantage of this extended transition period until the first to occur of the date that we ( i ) are no longer an “ emerging growth company ” or ( ii ) affirmatively and irrevocably opt out of this extended transition period . we have elected to take advantage of the benefits of this extended transition period . our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards . until the date that we are no longer an “ emerging growth company ” or affirmatively and irrevocably opt out of the exemption provided by securities act section 7 ( a ) ( 2 ) ( b ) , upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies , we will disclose the date on which adoption is required for non-emerging growth companies and the date on which we will adopt the recently issued accounting standard . 44 index this management 's discussion and analysis of financial condition and results of operations is based on our financial statements , which have been prepared in accordance with accounting principles generally accepted in the united states of america , or gaap . the preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets , liabilities , revenues and expenses . on an ongoing basis , we evaluate these estimates and assumptions , including those described below . we base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances . these estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources . actual results and experiences may differ materially from these estimates . some of the estimates and assumptions we have to make under gaap require difficult , subjective and or complex judgments about matters that are inherently uncertain and , as a result , actual results could differ from those estimates . due to the estimation processes involved , the following summarized accounting policies and their application are considered to be critical to understanding our business operations , financial condition and results of operations . stock-based compensation stock-based compensation cost is measured at grant date , based on the estimated fair value of the award , and is recognized as expense over the employee 's requisite service period on a straight-line basis . we account for stock options granted to non-employees on a fair value basis using the black-scholes option pricing model . the non-cash charge to operations for non-employee options with vesting are revalued at the end of each reporting period based upon the change in the fair value of the options and amortized to consulting expense over the related contract service period . for the purpose of valuing options and warrants granted to our employees , non-employees and directors and officers during the year ended december 31 , 2013 , we used the black-scholes option pricing model . we granted options to purchase an aggregate of 84,134 shares of common stock during the year ended december 31 , 2013. the options were granted to non-executive employees . to determine the risk-free interest rate , we utilized the u.s. treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards . the expected term of the options granted is in accordance with staff accounting bulletin 107 which is based the average between vesting term and contractual term . the expected dividend yield reflects our current and expected future policy for dividends on our common stock . the expected stock price volatility for our stock options was calculated by examining historical volatilities for similar publicly traded industry peers , since we do not have any trading history for our common stock . we will continue to analyze the expected stock price volatility and expected term assumptions as historical data for our common stock becomes available . we have not experienced any material forfeitures of stock options and as such , have not established a forfeiture rate . since the stock options currently outstanding are primarily held by our senior management and directors , we will continue to evaluate the effects of such future potential forfeitures , as they may arise , to evaluate our estimated forfeiture rate . due to our limited history , we use the simplified method to determine the expected life of the option grants . research and development costs our expenses include all research and development costs as incurred including the disposition of plasma and equipment for which there is no alternative future use . such expenses include costs associated with planning and conducting clinical trials . 45 index our agreement with biotest includes the in-license of certain rights to

